Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionDNA-binding transcription factor activity, RNA polymerase II-specific

ZNF75D ZNF75CP CPHXL2 YLPM1 MEOX2 NFX1

1.38e-041412136GO:0000981
GeneOntologyMolecularFunctionRNA polymerase II transcription regulatory region sequence-specific DNA binding

ZNF75D ZNF75CP CPHXL2 MEOX2 NFX1

1.62e-031459135GO:0000977
Domain-

MYO15A SBNO1 YLPM1

8.23e-037461133.40.50.300
DomainP-loop_NTPase

MYO15A SBNO1 YLPM1

1.17e-02848113IPR027417
PathwayREACTOME_GENE_SILENCING_BY_RNA

NUP43 TNRC6B

2.46e-044972MM14837
Pubmed

The ZNF75 zinc finger gene subfamily: isolation and mapping of the four members in humans and great apes.

ZNF75D ZNF75CP

7.74e-0741328661144
Pubmed

A protein-protein interaction map of the TNF-induced NF-κB signal transduction pathway.

NUP43 TNRC6B PRRC2A YLPM1

3.75e-0630213430561431
Pubmed

Comparative Application of BioID and TurboID for Protein-Proximity Biotinylation.

NUP43 TNRC6B FAM222B YLPM1

1.92e-0545713432344865
Pubmed

Human Immunodeficiency Virus Type 1 Vpr Mediates Degradation of APC1, a Scaffolding Component of the Anaphase-Promoting Complex/Cyclosome.

SBNO1 TNRC6B PRRC2A

9.04e-0524213334011540
Pubmed

A Degradation Motif in STAU1 Defines a Novel Family of Proteins Involved in Inflammation.

TNRC6B PRRC2A YLPM1 NFX1

1.15e-0472413436232890
Pubmed

Proximity labeling reveals dynamic changes in the SQSTM1 protein network.

TNRC6B FAM222B NFX1

2.10e-0432213339098523
InteractionB9D2 interactions

NUP43 TNRC6B YLPM1

7.37e-0673113int:B9D2
InteractionTASOR2 interactions

NUP43 MEOX2 NFX1

2.02e-05102113int:TASOR2
InteractionAATF interactions

NUP43 PRRC2A YLPM1 NFX1

3.55e-05376114int:AATF
InteractionRBMX interactions

NUP43 PRRC2A YLPM1 NFX1

7.85e-05461114int:RBMX
InteractionKIZ interactions

TNRC6B MEOX2

9.44e-0527112int:KIZ
InteractionMEX3B interactions

TNRC6B PRRC2A NFX1

2.04e-04222113int:MEX3B
InteractionEIF3G interactions

PRRC2A MEOX2 NFX1

2.86e-04249113int:EIF3G
InteractionBMI1 interactions

TNRC6B PRRC2A YLPM1 NFX1

3.11e-04659114int:BMI1
InteractionNCK2 interactions

PRRC2A YLPM1 MEOX2

3.32e-04262113int:NCK2
InteractionSSRP1 interactions

NUP43 SBNO1 PRRC2A YLPM1

3.61e-04685114int:SSRP1
InteractionBEX1 interactions

PRRC2A MEOX2

3.68e-0453112int:BEX1
InteractionUQCR11 interactions

PRRC2A YLPM1

3.68e-0453112int:UQCR11
InteractionSAA1 interactions

PRRC2A YLPM1

3.82e-0454112int:SAA1
InteractionKPLCE interactions

NUP43 NFX1

3.82e-0454112int:KPLCE
InteractionCFAP141 interactions

PRRC2A NFX1

3.96e-0455112int:CFAP141
InteractionTNRC6B interactions

NUP43 TNRC6B PRRC2A

4.12e-04282113int:TNRC6B
InteractionCELF1 interactions

TNRC6B PRRC2A YLPM1

4.38e-04288113int:CELF1
InteractionPRRC2C interactions

NUP43 PRRC2A NFX1

4.47e-04290113int:PRRC2C
InteractionMAGED1 interactions

TNRC6B PRRC2A MEOX2

4.70e-04295113int:MAGED1
InteractionFUBP3 interactions

TNRC6B PRRC2A YLPM1

4.79e-04297113int:FUBP3
InteractionAPBA3 interactions

TNRC6B NFX1

4.87e-0461112int:APBA3
InteractionEIF4ENIF1 interactions

NUP43 TNRC6B PRRC2A

4.93e-04300113int:EIF4ENIF1
InteractionCNOT1 interactions

NUP43 TNRC6B PRRC2A

5.18e-04305113int:CNOT1
InteractionFUS interactions

NUP43 PRRC2A YLPM1 NFX1

5.28e-04757114int:FUS
InteractionCHD3 interactions

NUP43 SBNO1 YLPM1 NFX1

5.28e-04757114int:CHD3
InteractionPAN3 interactions

TNRC6B PRRC2A

5.53e-0465112int:PAN3
InteractionYTHDF2 interactions

TNRC6B PRRC2A NFX1

5.53e-04312113int:YTHDF2
InteractionNR1D2 interactions

NUP43 MEOX2

5.87e-0467112int:NR1D2
InteractionSMG7 interactions

TNRC6B PRRC2A YLPM1

5.90e-04319113int:SMG7
InteractionBYSL interactions

NUP43 MEOX2 NFX1

7.47e-04346113int:BYSL
InteractionCTIF interactions

TNRC6B PRRC2A

7.75e-0477112int:CTIF
InteractionHDLBP interactions

TNRC6B PRRC2A YLPM1 NFX1

8.36e-04855114int:HDLBP
InteractionSMG5 interactions

TNRC6B PRRC2A

9.21e-0484112int:SMG5
InteractionSMG6 interactions

PRRC2A MEOX2

9.43e-0485112int:SMG6
InteractionDDX60 interactions

NUP43 PRRC2A

9.43e-0485112int:DDX60
InteractionXPA interactions

NUP43 MEOX2

9.66e-0486112int:XPA
InteractionXRN2 interactions

NUP43 YLPM1 NFX1

9.88e-04381113int:XRN2
InteractionMKRN2 interactions

TNRC6B PRRC2A NFX1

1.02e-03385113int:MKRN2
InteractionSNRPF interactions

YLPM1 MEOX2 NFX1

1.02e-03385113int:SNRPF
InteractionGNL2 interactions

NUP43 PRRC2A NFX1

1.03e-03386113int:GNL2
InteractionRB1CC1 interactions

TNRC6B YLPM1 NFX1

1.03e-03387113int:RB1CC1
InteractionDRG1 interactions

PRRC2A MEOX2 NFX1

1.04e-03388113int:DRG1
InteractionPRRC2A interactions

TNRC6B PRRC2A NFX1

1.05e-03389113int:PRRC2A
InteractionPRMT2 interactions

PRRC2A YLPM1

1.08e-0391112int:PRMT2
InteractionRERE interactions

NUP43 PRRC2A

1.13e-0393112int:RERE
InteractionCNOT6L interactions

TNRC6B PRRC2A

1.13e-0393112int:CNOT6L
InteractionMLLT6 interactions

NUP43 MEOX2

1.18e-0395112int:MLLT6
InteractionFGA interactions

PRRC2A MEOX2

1.18e-0395112int:FGA
InteractionPOM121C interactions

NUP43 MEOX2

1.30e-03100112int:POM121C
InteractionNUP35 interactions

TNRC6B FAM222B YLPM1

1.35e-03424113int:NUP35
InteractionDDX17 interactions

NUP43 YLPM1 NFX1

1.36e-03426113int:DDX17
InteractionFXR2 interactions

TNRC6B PRRC2A NFX1

1.40e-03430113int:FXR2
InteractionEIF4G1 interactions

NUP43 YLPM1 NFX1

1.43e-03433113int:EIF4G1
InteractionERF interactions

NUP43 MEOX2

1.43e-03105112int:ERF
InteractionANKHD1-EIF4EBP3 interactions

TNRC6B PRRC2A

1.52e-03108112int:ANKHD1-EIF4EBP3
InteractionANKRD50 interactions

PRRC2A YLPM1

1.52e-03108112int:ANKRD50
InteractionPABPC4 interactions

PRRC2A YLPM1 NFX1

1.52e-03442113int:PABPC4
InteractionH2BC9 interactions

SBNO1 PRRC2A YLPM1

1.56e-03446113int:H2BC9
InteractionCAPRIN1 interactions

TNRC6B PRRC2A NFX1

1.61e-03451113int:CAPRIN1
InteractionCNOT11 interactions

TNRC6B PRRC2A

1.63e-03112112int:CNOT11
InteractionC10orf88 interactions

TNRC6B MEOX2

1.66e-03113112int:C10orf88
InteractionP4HA3 interactions

YLPM1 MEOX2

1.66e-03113112int:P4HA3
ComputationalGenes in the cancer module 285.

MYO15A ZNF75D

7.18e-044992MODULE_285
DrugKaempferol [520-18-3]; Down 200; 14uM; MCF7; HT_HG-U133A

SBNO1 PRRC2A YLPM1 NFX1

1.61e-061941147196_DN
Drug(+) -Levobunolol hydrochloride [47141-41-3]; Up 200; 12.2uM; PC3; HT_HG-U133A

TNRC6B ZNF75D MEOX2 NFX1

1.75e-061981146635_UP
DrugPicrotoxinin [17617-45-7]; Down 200; 13.6uM; PC3; HT_HG-U133A

MYO15A ZNF75D NFX1

9.70e-051951134260_DN
Drugrosiglitazone; Up 200; 10uM; MCF7; HT_HG-U133A

MYO15A YLPM1 NFX1

9.85e-051961136950_UP
DrugQuipazine dimaleate salt [4774-24-7]; Up 200; 9uM; HL60; HG-U133A

SBNO1 YLPM1 NFX1

1.00e-041971131789_UP
DrugOxyphenbutazone [129-20-4]; Down 200; 12.4uM; MCF7; HT_HG-U133A

TNRC6B YLPM1 NFX1

1.00e-041971133582_DN
DrugPapaverine hydrochloride [61-25-6]; Down 200; 10.6uM; MCF7; HT_HG-U133A

SBNO1 YLPM1 NFX1

1.00e-041971132747_DN
DrugFlunixin meglumine [42461-84-7]; Down 200; 8.2uM; MCF7; HT_HG-U133A

PRRC2A FAM222B YLPM1

1.00e-041971133411_DN
DrugAdiphenine hydrochloride [50-42-0]; Down 200; 11.4uM; MCF7; HT_HG-U133A

TNRC6B YLPM1 NFX1

1.00e-041971137037_DN
DrugProtoveratrine A [143-57-7]; Down 200; 5uM; MCF7; HT_HG-U133A

TNRC6B ZNF75D NFX1

1.00e-041971134963_DN
DrugPanthenol (D) [81-13-0]; Down 200; 19.4uM; PC3; HT_HG-U133A

TNRC6B YLPM1 NFX1

1.02e-041981131802_DN
DrugDimaprit dihydrochloride [23256-33-9]; Up 200; 17uM; MCF7; HT_HG-U133A

MYO15A TNRC6B ZNF75D

1.02e-041981136520_UP
DrugIopamidol [60166-93-0]; Down 200; 5.2uM; MCF7; HT_HG-U133A

PRRC2A YLPM1 NFX1

1.02e-041981137189_DN
DrugBuflomedil hydrochloride [35543-24-9]; Down 200; 11.6uM; PC3; HT_HG-U133A

MYO15A ZNF75D NFX1

1.02e-041981134258_DN
DrugGuanethidine sulfate [60-02-6]; Down 200; 13.4uM; PC3; HT_HG-U133A

TNRC6B ZNF75D NFX1

1.02e-041981135731_DN
DrugDoxepin hydrochloride [1229-29-4]; Down 200; 12.6uM; PC3; HT_HG-U133A

SBNO1 TNRC6B YLPM1

1.03e-041991136337_DN
DrugNevirapine

MRC1 MEOX2

1.40e-03117112ctd:D019829
Drugfluphenazine dihydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A_EA

TNRC6B ZNF75D

2.88e-031691121075_UP
Drug15d-PGJ2; Up 200; 10uM; MCF7; HT_HG-U133A

YLPM1 NFX1

2.88e-031691126948_UP
Drug5182598; Up 200; 25uM; MCF7; HT_HG-U133A_EA

PRRC2A NFX1

3.16e-03177112976_UP
DrugPhenoxybenzamine hydrochloride [63-92-3]; Down 200; 11.8uM; PC3; HT_HG-U133A

TNRC6B YLPM1

3.16e-031771124652_DN
DrugMefloquine hydrochloride [51773-92-3]; Up 200; 9.6uM; MCF7; HT_HG-U133A

TNRC6B ZNF75D

3.33e-031821126205_UP
Drugnitrite

PRRC2A NFX1

3.41e-03184112CID000024529
Drugwortmannin from Penicillium funiculosum; Up 200; 0.01uM; MCF7; HT_HG-U133A_EA

TNRC6B YLPM1

3.41e-031841121081_UP
DrugTriamcinolone [124-94-7]; Up 200; 10.2uM; HL60; HG-U133A

YLPM1 NFX1

3.55e-031881121395_UP
DrugScoulerine [6451-73-6]; Up 200; 12.2uM; HL60; HG-U133A

YLPM1 NFX1

3.59e-031891121742_UP
Drugcarbamazepine; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA

TNRC6B ZNF75D

3.59e-03189112835_UP
DrugDiflunisal [22494-42-4]; Down 200; 16uM; HL60; HG-U133A

TNRC6B PRRC2A

3.63e-031901121990_DN
DrugAmpyrone [83-07-8]; Down 200; 19.6uM; PC3; HT_HG-U133A

SBNO1 ZNF75D

3.63e-031901124507_DN
DrugLY 294002; Up 200; 10uM; MCF7; HT_HG-U133A

YLPM1 NFX1

3.63e-031901126956_UP
DrugHomochlorcyclizine dihydrochloride [1982-36-1]; Up 200; 10.4uM; MCF7; HT_HG-U133A

MYO15A ZNF75D

3.66e-031911127417_UP
DrugHarpagoside [19210-12-9]; Down 200; 8uM; MCF7; HT_HG-U133A

FAM222B YLPM1

3.66e-031911124981_DN
DrugRapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA

TNRC6B YLPM1

3.66e-031911121080_UP
DrugCeforanide [60925-61-3]; Down 200; 7.6uM; MCF7; HT_HG-U133A

TNRC6B ZNF75D

3.66e-031911125351_DN
Drugwortmannin from Penicillium funiculosum; Up 200; 0.01uM; MCF7; HT_HG-U133A

ZNF75D YLPM1

3.66e-031911126959_UP
Drug2-propylpentanoic acid; Up 200; 1000uM; MCF7; HG-U133A

PRRC2A YLPM1

3.70e-0319211223_UP
DrugRisperidone [106266-06-2]; Down 200; 9.8uM; HL60; HT_HG-U133A

TNRC6B ZNF75D

3.70e-031921122947_DN
Drug(+)-Isoproterenol (+)-bitartrate salt [14638-70-1]; Down 200; 11uM; HL60; HT_HG-U133A

MYO15A YLPM1

3.70e-031921123046_DN
DrugFenoterol hydrobromide [1944-12-3]; Down 200; 10.4uM; HL60; HT_HG-U133A

TNRC6B NFX1

3.70e-031921122378_DN
Drugpioglitazone HCl; Up 200; 10uM; PC3; HT_HG-U133A

ZNF75D NFX1

3.74e-031931126893_UP
Drugtroglitazone; Up 200; 10uM; MCF7; HT_HG-U133A

YLPM1 NFX1

3.74e-031931126949_UP
DrugPhenazopyridine hydrochloride [136-40-3]; Down 200; 16uM; PC3; HT_HG-U133A

FAM222B NFX1

3.74e-031931125758_DN
DrugEpitiostanol [2363-58-8]; Up 200; 13uM; MCF7; HT_HG-U133A

ZNF75D NFX1

3.74e-031931124788_UP
DrugThioguanosine [85-31-4]; Up 200; 12.6uM; PC3; HT_HG-U133A

MYO15A YLPM1

3.74e-031931126643_UP
DrugBisacodyl [603-50-9]; Down 200; 11uM; PC3; HT_HG-U133A

YLPM1 NFX1

3.74e-031931124616_DN
DrugClotrimazole [23593-75-1]; Down 200; 11.6uM; HL60; HG-U133A

FAM222B YLPM1

3.74e-031931121549_DN
DrugNorfloxacin [70458-96-7]; Down 200; 12.6uM; MCF7; HT_HG-U133A

ZNF75D NFX1

3.74e-031931125985_DN
DrugKetoprofen [22071-15-4]; Down 200; 15.8uM; PC3; HT_HG-U133A

TNRC6B NFX1

3.74e-031931124286_DN
DrugTiratricol, 3,3',5-triiodothyroacetic acid [51-24-1]; Down 200; 6.4uM; HL60; HG-U133A

SBNO1 YLPM1

3.74e-031931121412_DN
DrugCefazolin sodium salt [27164-46-1]; Up 200; 8.4uM; PC3; HT_HG-U133A

MYO15A ZNF75D

3.74e-031931127385_UP
DrugHalcinonide [3093-35-4]; Down 200; 8.8uM; HL60; HT_HG-U133A

ZNF75D FAM222B

3.78e-031941122185_DN
DrugTrichostatin A, Streptomyces sp.; Down 200; 0.1uM; HL60; HT_HG-U133A

MYO15A ZNF75D

3.78e-031941126171_DN
Drug(-)-Quinpirole hydrochloride [85760-74-3]; Down 200; 15.6uM; MCF7; HT_HG-U133A

YLPM1 NFX1

3.78e-031941127481_DN
DrugPentylenetetrazole [54-95-5]; Down 200; 29uM; HL60; HG-U133A

PRRC2A NFX1

3.78e-031941121408_DN
DrugICI 182,780; Up 200; 0.01uM; MCF7; HT_HG-U133A

ZNF75D YLPM1

3.78e-031941126955_UP
DrugNifurtimox [23256-30-6]; Down 200; 14uM; MCF7; HT_HG-U133A

YLPM1 NFX1

3.78e-031941124953_DN
DrugPF-01378883-00 [351320-41-7]; Up 200; 10uM; PC3; HT_HG-U133A

MYO15A NFX1

3.78e-031941126368_UP
Drugtrifluoperazine dihydrochloride; Down 200; 10uM; HL60; HT_HG-U133A

FAM222B NFX1

3.78e-031941122684_DN
DrugEpivincamine [6835-99-0]; Up 200; 11.2uM; HL60; HG-U133A

ZNF75D PRRC2A

3.78e-031941121783_UP
DrugCyclizine hydrochloride [303-25-3]; Down 200; 13.2uM; MCF7; HT_HG-U133A

YLPM1 NFX1

3.78e-031941122880_DN
Drugprazosin hydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A_EA

PRRC2A YLPM1

3.78e-03194112942_UP
DrugTetrahydrozoline hydrochloride [522-48-5]; Up 200; 16.8uM; MCF7; HT_HG-U133A

ZNF75D NFX1

3.78e-031941126769_UP
DrugAlexidine dihydrochloride [22573-93-9]; Down 200; 6.8uM; MCF7; HT_HG-U133A

PRRC2A YLPM1

3.78e-031941124721_DN
Drugalpha-estradiol; Down 200; 0.01uM; MCF7; HT_HG-U133A_EA

TNRC6B PRRC2A

3.78e-03194112990_DN
DrugEthynylestradiol 3-methyl ether [72-33-3]; Up 200; 12.8uM; MCF7; HT_HG-U133A

MEOX2 NFX1

3.81e-031951124792_UP
DrugBenzocaine [94-09-7]; Down 200; 24.2uM; PC3; HT_HG-U133A

ZNF75D NFX1

3.81e-031951124224_DN
DrugPodophyllotoxin [518-28-5]; Down 200; 9.6uM; MCF7; HT_HG-U133A

ZNF75D PRRC2A

3.81e-031951127198_DN
DrugCarbarsone [121-59-5]; Up 200; 15.4uM; PC3; HT_HG-U133A

ZNF75D NFX1

3.81e-031951123991_UP
DrugHesperidin [520-26-3]; Up 200; 6.6uM; MCF7; HT_HG-U133A

FAM222B YLPM1

3.81e-031951125313_UP
DrugAmoxapine [14028-44-5]; Down 200; 12.8uM; PC3; HT_HG-U133A

ZNF75D NFX1

3.81e-031951126650_DN
DrugPhenazopyridine hydrochloride [136-40-3]; Down 200; 16uM; MCF7; HT_HG-U133A

PRRC2A FAM222B

3.81e-031951126234_DN
DrugThiamphenicol [15318-45-3]; Down 200; 11.2uM; HL60; HT_HG-U133A

TNRC6B ZNF75D

3.81e-031951121867_DN
DrugPivmecillinam hydrochloride [32887-03-9]; Down 200; 8.4uM; HL60; HT_HG-U133A

ZNF75D NFX1

3.81e-031951122973_DN
DrugBufexamac [2438-72-4]; Down 200; 18uM; MCF7; HT_HG-U133A

TNRC6B YLPM1

3.81e-031951127413_DN
DrugFamotidine [76824-35-6]; Up 200; 11.8uM; PC3; HG-U133A

FAM222B YLPM1

3.81e-031951121946_UP
DrugDisopyramide [3737-09-5]; Down 200; 11.8uM; MCF7; HT_HG-U133A

FAM222B NFX1

3.81e-031951127035_DN
DrugTolazamide [1156-19-0]; Up 200; 12.8uM; PC3; HT_HG-U133A

MYO15A NFX1

3.81e-031951124003_UP
DrugHomosalate [118-56-9]; Down 200; 15.2uM; PC3; HT_HG-U133A

TNRC6B NFX1

3.81e-031951124533_DN
DrugAcacetin [480-44-4]; Down 200; 14uM; PC3; HT_HG-U133A

PRRC2A YLPM1

3.81e-031951124324_DN
DrugOxethazaine [126-27-2]; Up 200; 8.6uM; PC3; HG-U133A

SBNO1 PRRC2A

3.81e-031951121903_UP
DrugQuinidine hydrochloride monohydrate [6151-40-2]; Down 200; 10.6uM; MCF7; HT_HG-U133A

TNRC6B NFX1

3.81e-031951123191_DN
DrugCyclopenthiazide [742-20-1]; Down 200; 10.6uM; PC3; HT_HG-U133A

ZNF75D NFX1

3.81e-031951124229_DN
DrugKetorolac tromethamine [74103-07-4]; Down 200; 10.6uM; HL60; HT_HG-U133A

ZNF75D PRRC2A

3.81e-031951123110_DN
DrugAsiaticoside [16830-15-2]; Down 200; 4.2uM; MCF7; HT_HG-U133A

TNRC6B NFX1

3.81e-031951127004_DN
DrugCiprofloxacin hydrochloride [93107-08-5]; Up 200; 10.8uM; MCF7; HT_HG-U133A

ZNF75D YLPM1

3.81e-031951125299_UP
DrugGlibenclamide [10238-21-8]; Down 200; 8uM; MCF7; HT_HG-U133A

TNRC6B NFX1

3.81e-031951123163_DN
DrugTamoxifen citrate [54965-24-1]; Down 200; 7uM; PC3; HT_HG-U133A

PRRC2A FAM222B

3.81e-031951122050_DN
DrugErythromycin [114-07-8]; Down 200; 5.4uM; MCF7; HT_HG-U133A

FAM222B YLPM1

3.81e-031951125329_DN
DrugAzlocillin sodium salt [37091-65-9]; Down 200; 8.2uM; HL60; HT_HG-U133A

TNRC6B ZNF75D

3.81e-031951122727_DN
Drugretinoic acid; Down 200; 1uM; MCF7; HT_HG-U133A

FAM222B NFX1

3.81e-031951126971_DN
DrugTrifluridine [70-00-8]; Up 200; 13.6uM; PC3; HT_HG-U133A

MYO15A NFX1

3.81e-031951125819_UP
DrugMethocarbamol [532-03-6]; Down 200; 16.6uM; MCF7; HT_HG-U133A

FAM222B NFX1

3.81e-031951127467_DN
Diseasebrain volume measurement

NUP43 SBNO1 MRC1 MEOX2

4.83e-05595114EFO_0006930
Diseaseirritable bowel syndrome

PRRC2A YLPM1

1.05e-03131112EFO_0000555
Diseasediastolic blood pressure, systolic blood pressure

MRC1 TNRC6B FAM222B

1.68e-03670113EFO_0006335, EFO_0006336
Diseasered blood cell density measurement

MYO15A TNRC6B FAM222B

3.65e-03880113EFO_0007978
Diseaseaspartate aminotransferase measurement

MYO15A MRC1 PRRC2A

3.93e-03904113EFO_0004736
Diseaseneuroimaging measurement, brain volume measurement

MRC1 MEOX2

4.86e-03286112EFO_0004346, EFO_0006930
Diseaseneuroimaging measurement

SBNO1 MRC1 TNRC6B

6.29e-031069113EFO_0004346
Diseasemean corpuscular hemoglobin concentration

MYO15A TNRC6B FAM222B

6.90e-031105113EFO_0004528
Diseasegrip strength measurement

TNRC6B PRRC2A

7.19e-03350112EFO_0006941
Diseaseaspartate aminotransferase measurement, serum alanine aminotransferase measurement, low density lipoprotein triglyceride measurement, body fat percentage, high density lipoprotein cholesterol measurement, sex hormone-binding globulin measurement

PRRC2A YLPM1

7.75e-03364112EFO_0004612, EFO_0004696, EFO_0004735, EFO_0004736, EFO_0007800, EFO_0009946

Protein segments in the cluster

PeptideGeneStartEntry
LHHPNNQTLSVNQQW

NUP43

101

Q8NFH3
EILAQLANQVWHNHN

MYO15A

2126

Q9UKN7
KPVTWNQHQLAHLQQ

FAM222B

361

Q8WU58
LQNQPWQKLRNEKHH

NFX1

101

Q12986
QQQQHQALQTNWHLP

MEOX2

81

P50222
QQNDWQYHPQQHQQP

CPHXL2

281

A0A1W2PPK0
LAVQQKQLWQQHHPQ

SBNO1

1371

A3KN83
KQLWQQHHPQSITNL

SBNO1

1376

A3KN83
HLNNWICQIQKGQTP

MRC1

771

P22897
LKQQQQHQWQQHQQG

PRRC2A

656

P48634
QNWVQKHHPQLAKQA

ZNF75CP

106

Q92670
KQLQAAAAHWQQHQQ

YLPM1

381

P49750
QNWVQKHHPQNVKQA

ZNF75D

106

P51815
QPEHKQQKLWHLFQN

TAPR1

51

Q14CZ0
RQPNSWNKQHQQQQP

TNRC6B

811

Q9UPQ9